WO2006120010A3 - Dibenzocycloheptanverbindungen und pharmazeutische mittel, welche diese verbindungen enthalten - Google Patents

Dibenzocycloheptanverbindungen und pharmazeutische mittel, welche diese verbindungen enthalten Download PDF

Info

Publication number
WO2006120010A3
WO2006120010A3 PCT/EP2006/004488 EP2006004488W WO2006120010A3 WO 2006120010 A3 WO2006120010 A3 WO 2006120010A3 EP 2006004488 W EP2006004488 W EP 2006004488W WO 2006120010 A3 WO2006120010 A3 WO 2006120010A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
dibenzocycloheptane
pharmaceuticals containing
immuno
tnf
Prior art date
Application number
PCT/EP2006/004488
Other languages
English (en)
French (fr)
Other versions
WO2006120010A2 (de
Inventor
Stefan Laufer
Wolfgang Albrecht
Cornelia Greim
Hans-Guenter Striegel
Karola Tollmann
Original Assignee
Merckle Gmbh
Stefan Laufer
Wolfgang Albrecht
Cornelia Greim
Hans-Guenter Striegel
Karola Tollmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merckle Gmbh, Stefan Laufer, Wolfgang Albrecht, Cornelia Greim, Hans-Guenter Striegel, Karola Tollmann filed Critical Merckle Gmbh
Priority to EP06742900A priority Critical patent/EP1881968A2/de
Priority to US11/914,078 priority patent/US20090105327A1/en
Priority to CA002608889A priority patent/CA2608889A1/en
Priority to JP2008510505A priority patent/JP2008544952A/ja
Publication of WO2006120010A2 publication Critical patent/WO2006120010A2/de
Publication of WO2006120010A3 publication Critical patent/WO2006120010A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D337/12—[b,e]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

Die vorliegende Erfindung betrifft Verbindungen der Formel (I), worin R1, R2, R3, R4, X und Y die in der Beschreibung angegebenen Bedeutungen besitzen. Die Verbindungen besitzen immunmodulierende und die Freisetzung von IL-1β und/oder TNF-α inhibierende bzw. regulierende Wirkung. Sie sind daher zur Behandlung von Erkrankungen brauchbar, die im Zusammenhang mit einer Störung des Immunsystems stehen.
PCT/EP2006/004488 2005-05-12 2006-05-12 Dibenzocycloheptanverbindungen und pharmazeutische mittel, welche diese verbindungen enthalten WO2006120010A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP06742900A EP1881968A2 (de) 2005-05-12 2006-05-12 Dibenzocycloheptanverbindungen und pharmazeutische mittel, welche diese verbindungen enthalten
US11/914,078 US20090105327A1 (en) 2005-05-12 2006-05-12 Dibenzocycloheptane compounds and pharmaceuticals containing these compounds
CA002608889A CA2608889A1 (en) 2005-05-12 2006-05-12 Dibenzocycloheptane compounds and pharmaceuticals containing these compounds
JP2008510505A JP2008544952A (ja) 2005-05-12 2006-05-12 ジベンゾシクロヘプタン化合物およびこれら化合物を含んでいる薬剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67996705P 2005-05-12 2005-05-12
DE102005022020A DE102005022020A1 (de) 2005-05-12 2005-05-12 Dibenzocycloheptanverbindungen und pharmazeutische Mittel, welche diese Verbindungen enthalten
US60/679,967 2005-05-12
DE102005022020.7 2005-05-12

Publications (2)

Publication Number Publication Date
WO2006120010A2 WO2006120010A2 (de) 2006-11-16
WO2006120010A3 true WO2006120010A3 (de) 2007-01-18

Family

ID=37310919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/004488 WO2006120010A2 (de) 2005-05-12 2006-05-12 Dibenzocycloheptanverbindungen und pharmazeutische mittel, welche diese verbindungen enthalten

Country Status (7)

Country Link
US (1) US20090105327A1 (de)
EP (1) EP1881968A2 (de)
JP (1) JP2008544952A (de)
CN (1) CN101223153A (de)
CA (1) CA2608889A1 (de)
DE (1) DE102005022020A1 (de)
WO (1) WO2006120010A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206534A1 (de) 2008-10-09 2010-07-14 c-a-i-r biosciences GmbH Dibenzocycloheptanonderivate und pharmazeutische Mittel, welche diese Verbindungen enthalten
SG174883A1 (en) * 2009-03-27 2011-11-28 Presidio Pharmaceuticals Inc Fused ring inhibitors of hepatitis c
WO2012040389A2 (en) 2010-09-22 2012-03-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
WO2012050918A2 (en) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
CN106631793B (zh) * 2016-10-19 2019-03-08 浙江师范大学 一种二苯并环庚烷衍生物的制备方法
WO2021038292A1 (en) * 2019-08-27 2021-03-04 Synovo Gmbh Centrally active p38alpha inhibiting compounds
WO2023186881A1 (en) 2022-03-29 2023-10-05 Baden-Württemberg Stiftung Ggmbh P38 map kinase inhibitors for use in the treatment of colorectal cancer
WO2023221981A1 (en) * 2022-05-16 2023-11-23 Bp Apollo Limited Taxamairin analogs and methods of use thereof
CN115385887B (zh) * 2022-06-08 2024-01-23 北京联本医药化学技术有限公司 一种铵盐离子液体催化环合反应制备伊索克酸的方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2224655A1 (de) * 1971-05-21 1972-12-07 Roussel-Uclaf, Paris Tricyclische Verbindungen und Verfahren zu deren Herstellung
JPS55108868A (en) * 1979-02-14 1980-08-21 Dai Ichi Seiyaku Co Ltd Dibenzoxepin derivative
JPS55124777A (en) * 1979-03-20 1980-09-26 Toa Eiyou Kagaku Kogyo Kk Novel dibenzoxepin derivative and its preparation
EP0115690A1 (de) * 1983-01-03 1984-08-15 American Home Products Corporation Dibenzocycloheptenylidenderivate
JPH0478774A (ja) * 1990-07-19 1992-03-12 Mazda Motor Corp 自動車の前部車体構造
EP0798288A1 (de) * 1995-10-16 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclische verbindungen
WO1998015549A1 (en) * 1996-10-04 1998-04-16 Novo Nordisk A/S N-substituted azaheterocyclic compounds
WO1998032730A1 (en) * 1997-01-24 1998-07-30 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Aminobenzophenones as inhibitors of interleukin and tnf
WO2003018535A2 (en) * 2001-08-28 2003-03-06 Leo Pharma A/S Novel aminobenzoephenones
EP1408033A1 (de) * 2001-06-27 2004-04-14 Ube Industries, Ltd. Dibenzocycloheptenverbindung
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
WO2005066161A1 (en) * 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL57077A0 (en) * 1978-04-21 1979-07-25 Syntex Inc 6,11-dihydrodibenzo-thiepin-11-one s-oxides their preparation and pharmaceutical compositions containing them
JPH03181443A (ja) * 1989-12-08 1991-08-07 Hisamitsu Pharmaceut Co Inc 新規なジベンゾ〔ａ，ｄ〕シクロヘプテン誘導体

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2224655A1 (de) * 1971-05-21 1972-12-07 Roussel-Uclaf, Paris Tricyclische Verbindungen und Verfahren zu deren Herstellung
JPS55108868A (en) * 1979-02-14 1980-08-21 Dai Ichi Seiyaku Co Ltd Dibenzoxepin derivative
JPS55124777A (en) * 1979-03-20 1980-09-26 Toa Eiyou Kagaku Kogyo Kk Novel dibenzoxepin derivative and its preparation
EP0115690A1 (de) * 1983-01-03 1984-08-15 American Home Products Corporation Dibenzocycloheptenylidenderivate
JPH0478774A (ja) * 1990-07-19 1992-03-12 Mazda Motor Corp 自動車の前部車体構造
EP0798288A1 (de) * 1995-10-16 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclische verbindungen
WO1998015549A1 (en) * 1996-10-04 1998-04-16 Novo Nordisk A/S N-substituted azaheterocyclic compounds
WO1998032730A1 (en) * 1997-01-24 1998-07-30 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Aminobenzophenones as inhibitors of interleukin and tnf
EP1408033A1 (de) * 2001-06-27 2004-04-14 Ube Industries, Ltd. Dibenzocycloheptenverbindung
WO2003018535A2 (en) * 2001-08-28 2003-03-06 Leo Pharma A/S Novel aminobenzoephenones
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
WO2005066161A1 (en) * 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; "6,11-Dihydro-11-oxodibenz[b,e]oxepin derivatives", XP002401551, retrieved from STN Database accession no. 1981:174914 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NISHIZAWA, SUSUMU ET AL: "Preparation of 6,11-dihydrodibenz[b,e]oxepin-11-ones", XP002401552, retrieved from STN Database accession no. 1997:702036 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YUKIMOTO YUSUKE: "DIBENZOXEPIN DERIVATIVE", XP002401553, retrieved from STN Database accession no. 1981:192172 *
ENGELHARDT E L ET AL: "STRUCTURE-ACTIVITY RELATIONSHIPS IN THE CYPROHEPTADINE SERIES", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 8, 1 November 1965 (1965-11-01), pages 829 - 835, XP000612118, ISSN: 0022-2623 *
KLUGE, A.F.; ET AL., J. MED. CHEM., vol. 21, no. 6, 1978, pages 529 - 536, XP002401528 *
LEESON, PAUL D. ET AL: "Transannular cyclizations of 5-(hydroxyamino)dibenzo[a,e]cyclooctatrienes. Regioselective synthesis of dibenzohomotropane analogs", JOURNAL OF ORGANIC CHEMISTRY , 55(7), 2094-103 CODEN: JOCEAH; ISSN: 0022-3263, 1990, XP002401529 *
PAVIA, M.R.; ET AL., J. MED. CHEM., vol. 35, 1992, pages 4238 - 4248, XP002401527 *
RYTTER OTTOSEN E ET AL: "Synthesis and Structure-Activity Relationship of Aminobenzophenones. A Novel Class of p38 MAP Kinase Inhibitors with High Antiinflammatory Activity", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 46, 2003, pages 5651 - 5662, XP002282566, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
US20090105327A1 (en) 2009-04-23
EP1881968A2 (de) 2008-01-30
CA2608889A1 (en) 2006-11-16
DE102005022020A1 (de) 2006-11-23
JP2008544952A (ja) 2008-12-11
CN101223153A (zh) 2008-07-16
WO2006120010A2 (de) 2006-11-16

Similar Documents

Publication Publication Date Title
WO2006120010A3 (de) Dibenzocycloheptanverbindungen und pharmazeutische mittel, welche diese verbindungen enthalten
WO2010040843A3 (de) Dibenzocycloheptanonderivate und pharmazeutische mittel, welche diese verbindungen enthalten
GEP20125643B (en) Aurora kinase modulators and method of using same
WO2008006547A3 (en) Pyrrolopyrimidines for pharmaceutical compositions
WO2007140385A3 (en) Thiazole compounds as cannabinoid receptor ligands and uses thereof
UA92355C2 (en) urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS
WO2009018909A3 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2007027238A3 (en) Jak kinase inhibitors and their uses
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2007103370A3 (en) Quinazoline derivatives as phosphodiesterase 10 inhibitors
CA2492096A1 (en) Cis-alkoxy-substituted spirocyclic 1-h-pyrrolidine-2,4-dione derivatives serving as pesticides
MX2008014500A (es) 2,4-diaminopirimidinas como inhibidores de quinasas de ciclo de celulas.
WO2007100880A8 (en) Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
HK1136283A1 (en) Compounds for the prevention and treatment of cardiovascular diseases
TN2011000245A1 (en) Organic compounds
WO2006100082A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
WO2009077471A3 (de) Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
WO2007106436A3 (en) Photoactive compounds and compositions and uses thereof
WO2006087120A3 (de) Pyrazolopyrimidine
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
WO2007092496A3 (en) 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
WO2009046842A3 (de) Thialzolderivate zur behandlung von krebs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2608889

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008510505

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2006742900

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 5715/CHENP/2007

Country of ref document: IN

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWE Wipo information: entry into national phase

Ref document number: 200680022970.5

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006742900

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11914078

Country of ref document: US